INDGN

What Indegene promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 17 tracked 6 delivered 3 missed 8 open
  • EBITDA Margin delivered said Q4 FY25 Promised: Fairly stable Q1 FY27: The promise pertained to FY26 and was achieved. No further updates applicable.
  • New Deal Contribution went quiet said Q3 FY25 Promised: $2 million to $4 million ACV each for five key deals Q1 FY27: No mention of these specific deals from FY25. The promise remains unaddressed and is now six quarters old.
  • EPS Accretion (BioPharm) on track said Q1 FY26 Promised: Accretive beyond 5-6 quarters Q1 FY27: The target period of 5-6 quarters from Q1 FY26 is approaching (ends Q2-Q3 FY27). No specific update on EPS accretion was provided, but overall business integration is proceeding.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 17 tracked commitments for Indegene — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens